Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119950 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 388
- Enrollment target
NCT01119950 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 388 participants.
The verdict
NCT01119950, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 388 participants
- Enrollment target
Study Summary
This study was designed to investigate the efficacy and safety of NVA237, a long-acting muscarinic antagonist, in patients with moderate to severe COPD.
Interventions
- DRUG NVA237 12.5 µg once daily
- DRUG NVA237 25.0 µg once daily
- DRUG NVA237 12.5 µg twice daily
- DRUG NVA237 50.0 µg once daily
- DRUG NVA237 25.0 µg twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119950
The ClinicalTrials.gov registry entry for NCT01119950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NVA237 12.5 µg once daily is the first listed.
NCT01119950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119950 about?
NCT01119950 is a clinical study titled "Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)". This study was designed to investigate the efficacy and safety of NVA237, a long-acting muscarinic antagonist, in patients with moderate to severe COPD.
What is the current status of trial NCT01119950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 388 participants. The study started on 2010-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01119950?
The interventions under investigation include: NVA237 12.5 µg once daily (DRUG), NVA237 25.0 µg once daily (DRUG), NVA237 12.5 µg twice daily (DRUG), NVA237 50.0 µg once daily (DRUG), NVA237 25.0 µg twice daily (DRUG).
Who is sponsoring clinical trial NCT01119950?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.